FLAG方案治疗难治复发急性髓系白血病的疗效及安全性研究

摘要

Objective To analyze the curative effect and safety of FLAG regimen in the treatment of relapsed acute myeloid leukemia (AML).Methods 70 patients with refractory recurrent AML treated in our hospital from July 2013 to July 2016 were selected and randomly divided into study group and control group.35 cases in the study group were treated with FLAG regimen,while 35 cases in the control group were treated with MEA regimen.After one course of treatment,the clinical efficacy and adverse reactions of the two groups were compared.Results After 1 course of treatment,the total effective rate in the study group was 74.29％,which was higher than 51.43％ in the control group,with statistically significant difference (x 2=3.92,P＜0.05).There was no statistically significant difference in hematologic adverse reactions between the two groups (P＞0.05);the total incidence of non-hematologic adverse reactions in the study group was 68.57％,which was significantly lower than 91.43％ in the control group,with statistically significant difference (P＜0.05).Conclusion The FLAG regimen in the treatment of refractory recurrent AML has high clinical efficacy,with low incidence of adverse reactions and high safety,worthy of clinical application and promotion.%目的 对FLAG方案治疗难治复发急性髓系白血病(AML)的临床疗效和安全性进行分析.方法 选择2013年7月至2016年7月本院收治的难治复发AML患者70例作为研究对象,随机将其均分为研究组和对照组,研究组35例给予FLAG方案治疗,对照组35例采用MEA方案治疗,分析比较1个疗程后两组的临床疗效和不良反应发生情况.结果 治疗1个疗程后,研究组总有效率74.29％显著高于对照组51.43％,差异有统计学意义(x 2=3.92,P＜0.05).两组均有不同程度不良反应发生,两组血液学不良反应总发生率无统计学差异(P＞0.05);在非血液学不良反应发生情况方面,研究组总发生率68.57％低于对照组91.43％,差异有统计学意义(P＜0.05).结论 FLAG方案用于治疗难治复发AML,临床疗效较高,不良反应发生率较低,安全性高,有临床大力推广应用的价值.